Georgia Medicare Cervical Cancer Screening 2026 Guide

Medicare covers cervical cancer screening for eligible women beneficiaries through a benefit codified at Section 1861(nn) of the Social Security Act (42 U.S.C. 1395x(nn)). The screening Pap test was established by Section 6113 of the Omnibus Budget Reconciliation Act of 1989 (OBRA 89, Public Law 101-239) with coverage effective July 1, 1990. The screening pelvic examination was added by Section 4102 of the Balanced Budget Act of 1997 (BBA, Public Law 105-33). Human papillomavirus (HPV) co-testing coverage was added through CMS coverage decision-making effective July 9, 2015 for women age 30 to 65 every 5 years. The implementing regulations are codified at 42 CFR 410.56.

For Georgia Medicare women beneficiaries, cervical cancer screening is a critically important preventive service with significant nuance in how it applies to the typical aging-in beneficiary population. Most Medicare women enroll at age 65, an age at which USPSTF guidance supports discontinuation of routine cervical cancer screening for women with adequate prior negative screening history (defined as three consecutive negative Pap tests or two consecutive negative HPV tests or co-tests within the past 10 years, with the most recent within the past 5 years). Many Medicare women therefore appropriately discontinue routine screening as they age in, while women without adequate prior screening, women with high-risk histories, and women under age 65 who enroll through disability eligibility require continued screening. Georgia's cervical cancer mortality disparities, particularly affecting African American and Hispanic women, make systematic discussion at the Annual Wellness Visit important for ensuring appropriate continuation or discontinuation decisions are made on the basis of individualized prior screening history rather than blanket assumptions. This guide explains the statutory framework, eligibility rules, covered modalities, HPV co-testing coverage, HCPCS coding, cost-sharing under the ACA Section 4104 waiver, USPSTF discontinuation criteria, colposcopy coordination after abnormal screening, and the Georgia gynecology landscape so beneficiaries, families, and clinicians can navigate the benefit effectively.

By Brevy Care Team

Part 1: The Statutory and Regulatory Framework

Section 1861(nn) of the Social Security Act

Section 1861(nn) of the Social Security Act (42 U.S.C. 1395x(nn)) defines "screening pap smear and screening pelvic examination" for Medicare coverage purposes. The statutory definition includes:

• A diagnostic laboratory test consisting of a routine exfoliative cytology test (Pap test) of cervical or vaginal cells.
• A screening pelvic examination including a clinical breast examination as part of the pelvic visit.
• HPV testing when furnished as part of a screening pelvic examination consistent with CMS coverage decisions.

The statute also requires that the screening be performed by a physician or qualified non-physician practitioner.

OBRA 1989 Section 6113 Origin of the Pap Test Coverage

The screening Pap test benefit was established by Section 6113 of the Omnibus Budget Reconciliation Act of 1989 (OBRA 89, Public Law 101-239), signed by President George H.W. Bush on December 19, 1989. The Pap test benefit became effective for services furnished on or after July 1, 1990. The original frequency was every 3 years for low-risk women, every 12 months for high-risk women.

BBA 1997 Section 4102 Pelvic Examination Addition

Section 4102 of the Balanced Budget Act of 1997 (BBA, Public Law 105-33), signed August 5, 1997, added the screening pelvic examination as a covered service. The pelvic examination is performed in conjunction with the Pap test and includes the clinical breast examination.

Frequency Updates Through CMS Rulemaking

CMS has updated the frequency rules through implementing regulations and National Coverage Determinations. The current frequency rules are:

• Average-risk women: Screening Pap test and pelvic examination every 24 months.
• High-risk women: Screening Pap test and pelvic examination every 12 months (annually).
• HPV co-testing: Every 5 years for women age 30 to 65 (per NCD 210.2 effective July 9, 2015).

HPV Co-Testing Coverage Expansion (NCD 210.2, July 9, 2015)

CMS issued National Coverage Determination 210.2 expanding Medicare coverage to include HPV testing in combination with Pap test (co-testing) for women age 30 to 65 effective July 9, 2015. The coverage applies once every 5 years for asymptomatic average-risk women age 30 to 65 who meet the screening criteria.

This expansion reflected accumulated evidence that HPV testing improves screening sensitivity, particularly for the detection of adenocarcinoma which is less well-detected by cytology alone. HPV testing also supports longer screening intervals (5 years for co-testing versus 3 years for cytology alone) because of higher negative predictive value.

42 CFR 410.56 Implementing Regulations

The implementing regulations for cervical and vaginal cancer screening are codified at 42 CFR 410.56. The regulations specify:

• The covered services: screening Pap test, screening pelvic examination, HPV co-testing.
• The frequency limits by risk category.
• The high-risk category definitions.
• The provider requirements (physician or qualified non-physician practitioner).
• The clinical laboratory requirements for cytopathology and HPV testing.

Related Statutory and Regulatory Authority

Several other Medicare preventive services statutes coordinate with the cervical cancer screening benefit:

• Section 1861(ww) SSA: Initial Preventive Physical Examination (IPPE, Welcome to Medicare visit).
• Section 1861(hhh) SSA: Annual Wellness Visit (AWV).
• Section 1861(ddd) SSA: General preventive services framework.
• ACA Section 4104 (Public Law 111-148), Preventive services cost-sharing waiver effective January 1, 2011.

Part 2: Eligible Beneficiaries

Sex Eligibility

Cervical cancer screening under Section 1861(nn) is specifically defined as a service for women beneficiaries.

Age Eligibility

Medicare covers cervical cancer screening for women beneficiaries without an explicit lower age limit (women under age 35 who enroll in Medicare through disability eligibility may receive screening). There is no upper age limit, but USPSTF guidance and CMS regulations recognize the appropriateness of discontinuing routine screening for women older than 65 with adequate prior negative screening history.

Risk Stratification

Medicare uses two risk categories for cervical cancer screening:

Average risk applies to women without any qualifying high-risk factor. Average-risk frequency is every 24 months for screening Pap test and pelvic examination.

High risk applies to women with at least one qualifying high-risk factor. High-risk frequency is every 12 months (annually).

High-Risk Category Definitions

The implementing regulations and CMS sub-regulatory guidance define the following high-risk categories for cervical cancer screening:

1. Personal history of cervical cancer or vaginal cancer: Prior diagnosis of cervical or vaginal cancer requires ongoing surveillance with annual screening.

2. Abnormal cytology within the past 3 years: Prior abnormal Pap test (ASCUS, LSIL, HSIL, AGC, AIS) within the past 3 years triggers high-risk classification.

3. History of cervical intraepithelial neoplasia (CIN) grade 2 or 3: Prior CIN 2 or CIN 3 lesions require ongoing surveillance.

4. DES exposure: Women exposed in utero to diethylstilbestrol (DES) prior to 1971 face elevated risk of clear cell adenocarcinoma of the cervix and vagina.

5. HIV infection or immunocompromise: HIV-infected women, organ transplant recipients on immunosuppressive therapy, and women receiving immunosuppressive treatment for autoimmune disease face elevated risk.

6. Other documented high-risk factors: Such factors may include certain occupational exposures, history of cervical pre-cancer treatment, and other documented risk factors at provider discretion.

USPSTF 2018 Recommendation Framework

The USPSTF 2018 update represents the current recommended framework:

• Women age 21 to 29: Pap test every 3 years (cytology alone). USPSTF does not recommend HPV testing for women under age 30 due to high HPV prevalence with low cancer progression risk.
• Women age 30 to 65: Three options, Pap test every 3 years (cytology alone), HPV testing every 5 years (primary HPV testing), or Pap and HPV co-testing every 5 years.
• Women older than 65: Recommend against screening for women with adequate prior negative screening (three consecutive negative Pap tests or two consecutive negative HPV tests/co-tests within past 10 years, most recent within past 5 years).
• Women with prior hysterectomy: Recommend against screening for women who have had a hysterectomy with removal of the cervix and who do not have a history of high-grade precancerous lesion or cervical cancer.

The USPSTF Grade A recommendation qualifies cervical cancer screening for the ACA Section 4104 cost-sharing waiver.

Discontinuation of Screening at Age 65

The USPSTF recommendation to discontinue routine screening for women older than 65 with adequate prior negative screening is particularly important for the Medicare population because most beneficiaries enroll at age 65. Many aging-in Medicare women appropriately discontinue routine cervical cancer screening based on their adequate prior screening history.

However, discontinuation requires documented adequate prior screening:

• Three consecutive negative Pap tests within the past 10 years, OR
• Two consecutive negative HPV tests or co-tests within the past 10 years.
• The most recent test should be within the past 5 years.

Women with inadequate prior screening, prior abnormal results, or other risk factors should continue screening per their individual risk profile.

Part 3: Covered Screening Modalities

Screening Pap Test (Cytology)

The Pap test (papanicolaou smear) collects cells from the cervix using a brush or spatula. The cells are then fixed and stained for cytologic examination under a microscope to identify atypical or malignant cells. Pap testing has been the foundation of cervical cancer screening since its widespread adoption in the 1950s.

Two technical approaches to Pap testing exist:

• Conventional Pap smear: Cells are smeared directly onto a glass slide at the bedside.
• Liquid-based cytology: Cells are suspended in a liquid preservative and processed in the laboratory. This is the dominant approach in modern practice.

Medicare covers both approaches with corresponding HCPCS codes.

Screening Pelvic Examination

The pelvic examination is a clinical examination performed by a physician or qualified non-physician practitioner. It typically includes:

• External examination: Inspection of the vulva and perineum.
• Speculum examination: Inspection of the vagina and cervix.
• Bimanual examination: Palpation of the uterus and adnexa.
• Clinical breast examination: Palpation of the breasts and axillae.

The pelvic examination is billed under HCPCS G0101 in conjunction with cervical cancer screening.

HPV Co-Testing

Human papillomavirus (HPV) testing identifies the presence of high-risk HPV types (most importantly HPV 16 and HPV 18, the leading high-risk HPV types associated with cervical cancer) through molecular testing of cervical samples. HPV co-testing combines HPV testing with cytology in a single screening encounter.

Medicare covers HPV testing as part of co-testing for women age 30 to 65 every 5 years under HCPCS G0476.

Coverage Code Summary

Coverage Code Combinations

A typical Medicare cervical cancer screening encounter generates multiple billing codes:

• The pelvic examination and clinical breast examination are billed under G0101.
• The act of obtaining the Pap sample and preparing/conveying it is billed under Q0091.
• The cytopathology interpretation in the laboratory is billed under one of the cytopathology codes depending on technique.
• HPV co-testing (when performed for women age 30-65 every 5 years) is billed under G0476.

Part 4: Cost-Sharing Structure

ACA Section 4104 Cost-Sharing Waiver

Section 4104 of the Affordable Care Act (Public Law 111-148) eliminated Part B deductible and coinsurance for USPSTF Grade A or B aligned preventive services effective January 1, 2011. The USPSTF has graded cervical cancer screening Grade A, qualifying it for the ACA Section 4104 cost-sharing waiver.

Therefore, for screening Pap test (Q0091 and cytopathology codes), pelvic examination (G0101), and HPV co-testing (G0476), Medicare beneficiaries pay $0 when the procedure is performed by a Medicare-accepting provider.

Cost-Sharing for Diagnostic Cervical Procedures

When a screening Pap test or HPV test identifies abnormal findings requiring additional evaluation, the beneficiary enters a diagnostic pathway with different cost-sharing. Typical diagnostic procedures include:

• Colposcopy: Direct visual examination of the cervix using a colposcope to identify abnormal areas for biopsy. Subject to standard Part B cost-sharing.
• Cervical biopsy: Tissue sampling from suspicious cervical areas during colposcopy. Subject to standard Part B cost-sharing.
• Endocervical curettage: Sampling of cells from the endocervical canal. Subject to standard Part B cost-sharing.
• LEEP (Loop Electrosurgical Excision Procedure): Therapeutic procedure for high-grade lesions. Subject to standard Part B cost-sharing.
• Cone biopsy: Excisional procedure for diagnosis or treatment of high-grade lesions. Subject to standard Part B cost-sharing.

Cost-Sharing Summary Table

Part 5: Coordination With Other Medicare Preventive Services

Coordination With the Annual Wellness Visit

The Annual Wellness Visit (AWV), authorized by Section 1861(hhh) of the Social Security Act, includes a personalized prevention plan that documents preventive services status and recommendations. Cervical cancer screening is a routine AWV component for women beneficiaries:

• Documentation of most recent Pap test, HPV test, or co-test results.
• Documentation of prior abnormal results and surveillance status.
• Risk assessment for high-risk categorization.
• Discussion of continuation versus discontinuation of routine screening at age 65 based on adequate prior screening history.
• Coordination with other preventive services.

Coordination With the Initial Preventive Physical Examination

The Initial Preventive Physical Examination (IPPE) authorized by Section 1861(ww) is the one-time preventive visit available within the first 12 months of Part B enrollment. The IPPE includes assessment of preventive services needs and orders for appropriate screening including cervical cancer screening when indicated.

Coordination With Colposcopy and Diagnostic Workup

Abnormal cervical cancer screening results require timely diagnostic workup. The American Society for Colposcopy and Cervical Pathology (ASCCP) maintains evidence-based management guidelines specifying triage of abnormal Pap and HPV results. Common pathways include:

• ASCUS Pap with positive HPV: Colposcopy.
• LSIL Pap: Colposcopy.
• HSIL Pap: Colposcopy with biopsy.
• AGC Pap: Colposcopy with endocervical curettage.
• AIS Pap: Colposcopy with endocervical curettage and possible cone biopsy.
• Persistent HPV without cytologic abnormality: Repeat testing or colposcopy depending on age and HPV type.

Coordination With Other Cancer Screening

Many female Medicare beneficiaries receive coordinated cancer screening, cervical, breast (mammography), and colorectal, through the same primary care or AWV visit cycle.

Part 6: Provider Requirements

Provider Categories

Cervical cancer screening services are performed by:

• Gynecologists: Obstetrician-gynecologists with subspecialty training in women's health.
• Family medicine physicians: Many family medicine physicians provide women's health services including cervical cancer screening.
• Internal medicine physicians: Some internists provide cervical cancer screening, particularly when integrated with primary care.
• Nurse practitioners and physician assistants: Within scope of practice and state licensure rules.
• Certified nurse-midwives: Within scope of practice.

Clinical Laboratory Requirements

Cytopathology screening and HPV testing are performed in Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories with appropriate accreditation for high-complexity testing. The clinical laboratory provides cytotechnologists who perform initial screening and cytopathologists (pathologists with cytopathology subspecialty) who interpret abnormal findings.

Georgia Provider Licensure

In Georgia, gynecologists, family medicine physicians, and internal medicine physicians are licensed by the Georgia Composite Medical Board. Nurse practitioners, physician assistants, and certified nurse-midwives are licensed by the relevant Georgia licensing boards.

Part 7: The Major Georgia Gynecology Landscape

Atlanta Metropolitan Area

The Atlanta metropolitan area has extensive gynecology and women's health capacity:

• Emory Gynecology: Academic gynecology at Emory University with comprehensive women's health services.
• Wellstar Women's Health: Network-wide women's health coverage across the north and west Atlanta metropolitan area.
• Piedmont Women's Health: Piedmont Healthcare women's health services.
• Northside Hospital Women's Services: Particularly strong women's health presence in the north Atlanta area.
• Grady Women's Center: Safety-net women's health serving central Atlanta.
• Emory Winship Cancer Institute Gynecologic Oncology: Comprehensive gynecologic oncology for cervical cancer treatment.

Augusta and East Georgia

Augusta University Women's Health serves east Georgia with academic gynecology and gynecologic oncology services through the Georgia Cancer Center.

Macon and Central Georgia

Atrium Health Navicent (Macon) and Coliseum Medical Centers provide women's health services for central Georgia.

Savannah and Coastal Georgia

Memorial Health (Savannah) and St. Joseph's Candler Health System provide women's health services for coastal Georgia.

Albany and Southwest Georgia

Phoebe Putney Memorial Hospital (Albany) is the primary women's health resource for southwest Georgia.

Athens and Northeast Georgia

Piedmont Athens Regional and St. Mary's Health Care System provide women's health services for the Athens area and northeast Georgia.

Federally Qualified Health Centers (FQHCs)

Georgia's FQHCs provide women's health and cervical cancer screening services for medically underserved populations. Many FQHCs partner with the Georgia Department of Public Health Breast and Cervical Cancer Program (BCCP) to provide screening services for uninsured women.

Rural Georgia Access

Many rural Georgia counties lack local gynecology providers. Beneficiaries in counties without local gynecology access typically receive cervical cancer screening from family medicine physicians or nurse practitioners. When abnormal screening requires colposcopy, beneficiaries typically travel to regional medical centers (Albany, Macon, Augusta, Savannah, Athens, Atlanta) for specialty care.

Part 8: Cervical Cancer Disease Burden in Georgia

Incidence and Mortality

Cervical cancer incidence in the United States has declined dramatically since the introduction of Pap test screening, but persistent disparities affect underserved populations. In Georgia, cervical cancer mortality is elevated in African American and Hispanic women compared to non-Hispanic white women, reflecting screening uptake disparities and access barriers.

African American Mortality Disparity

African American women face elevated cervical cancer mortality rates nationally compared to non-Hispanic white women. This disparity reflects:

• Lower screening uptake.
• Later-stage diagnosis at presentation.
• Treatment access disparities.
• Persistent socioeconomic health disparities.

Hispanic Mortality Disparity

Hispanic women face cervical cancer incidence rates elevated above non-Hispanic white women, particularly among immigrant populations with limited screening access in countries of origin.

Georgia Department of Public Health Breast and Cervical Cancer Program

The Georgia Department of Public Health operates the Breast and Cervical Cancer Program (BCCP), which provides cervical cancer screening for uninsured low-income women. Women diagnosed with cervical cancer or pre-cancer through BCCP qualify for Medicaid coverage under the Breast and Cervical Cancer Prevention and Treatment Act of 2000 (42 U.S.C. 1396a(a)(10)(A)(ii)(XVIII)). This pathway primarily serves women under age 65; Medicare women beneficiaries generally receive screening under Medicare rather than BCCP.

HPV Vaccination Impact

The HPV vaccine, recommended for adolescents and young adults, is expected to substantially reduce cervical cancer incidence in future cohorts. However, the impact on the current Medicare population is limited because most Medicare women aged out of the vaccination age range before the vaccine became available. The vaccine impact will become more relevant for Medicare cohorts after the early HPV-vaccinated cohorts (born approximately 1990 and later) age into Medicare in the 2050s.

Part 9: Worked Examples

Worked Example 1: Atlanta Age 66 First Medicare Cervical Screening (No Adequate Prior)

Beneficiary: 66-year-old woman in Fulton County, no prior Pap test in past 10 years, average risk.

At her AWV with her primary care physician at Grady Health System, the physician documents the lack of adequate prior screening. Because the beneficiary does not meet the USPSTF criteria for discontinuation (three consecutive negative Pap tests within past 10 years, most recent within past 5 years), she requires continued screening rather than discontinuation.

The physician orders cervical and pelvic examination (G0101), Pap smear obtaining/preparing/conveying (Q0091), and HPV co-testing (G0476). The Pap and HPV testing is sent to the Grady cytopathology laboratory.

Results: Pap test negative for intraepithelial lesion or malignancy (NILM). HPV testing negative for high-risk types. The beneficiary now has one negative Pap and one negative HPV co-test. Per USPSTF guidance, she would need additional negative screenings before meeting the adequate prior screening criteria for discontinuation.

Billing: G0101, Q0091, cytopathology code, and G0476 all subject to ACA Section 4104 waiver. Beneficiary pays $0.

She is scheduled for her next co-testing in 5 years (at approximately age 71). If she has been continuously screened with negative results, she may meet discontinuation criteria at that time.

Worked Example 2: Rural Southwest Georgia Gynecology Access

Beneficiary: 67-year-old woman in Worth County, no local gynecologist, family medicine physician at FQHC handles women's health.

Her FQHC primary care physician documents the absence of adequate prior screening (she has not had a Pap test in over 10 years). She performs the cervical and pelvic examination (G0101), obtains the Pap sample (Q0091), and sends to Quest Diagnostics for liquid-based cytology (G0123) and HPV co-testing (G0476).

Results: Pap test ASCUS with positive HPV. This abnormal result triggers colposcopy referral. The nearest gynecologist with colposcopy capability is at Phoebe Putney in Albany, 30 miles away.

Colposcopy at Phoebe Putney shows acetowhite changes on the cervix. Biopsy of the suspicious area shows CIN 1. ASCCP guidelines support observation rather than immediate treatment for CIN 1 in women her age. She is scheduled for repeat HPV co-testing in 12 months.

Billing: Screening services (G0101, Q0091, G0123, G0476) under ACA Section 4104 waiver, $0 to beneficiary. Colposcopy (CPT 57452) and biopsy (57454) subject to standard Part B cost-sharing.

Worked Example 3: High-Risk Previous CIN History Annual Screening

Beneficiary: 64-year-old woman in Cobb County, history of CIN 2 treated with LEEP at age 58.

The CIN 2 history places her in the high-risk category requiring annual screening rather than every-24-months average-risk screening. Her gynecologist at Wellstar Women's Health orders annual Pap test and HPV co-testing.

Procedure: G0101, Q0091, G0123 cytopathology, G0476 HPV co-testing.

Results: Pap test NILM, HPV negative. Continued annual surveillance recommended given prior CIN 2 history.

Billing: All screening services subject to ACA Section 4104 waiver, $0 to beneficiary.

Worked Example 4: Age 68 Discontinuation Per Adequate Prior Negative Screening

Beneficiary: 68-year-old woman in DeKalb County, three consecutive negative Pap tests at ages 60, 63, and 66, most recent within past 5 years.

She has documented adequate prior negative screening per USPSTF criteria and is appropriately a candidate for discontinuation of routine screening. At her AWV at Emory, her primary care physician documents the adequate prior screening history and the USPSTF Grade A recommendation against continued screening for women older than 65 with adequate prior negative screening.

The beneficiary and physician engage in shared decision-making and the beneficiary elects to discontinue routine cervical cancer screening. The physician documents the decision in the AWV personalized prevention plan.

The beneficiary understands that diagnostic evaluation will be available if symptoms develop (postmenopausal bleeding, abnormal discharge).

Worked Example 5: HPV Co-Testing 5-Year Interval for Age 64

Beneficiary: 64-year-old woman in Bibb County, previously screened with co-testing every 5 years, last screening at age 59.

She is due for her 5-year HPV co-testing. Her primary care physician at Atrium Health Navicent orders cervical and pelvic examination (G0101), Pap smear obtaining (Q0091), liquid-based cytology (G0123), and HPV co-testing (G0476).

Results: Pap test NILM, HPV negative.

Billing: All screening services under ACA Section 4104 waiver, $0 to beneficiary.

She is scheduled for her next HPV co-testing in 5 years at age 69. At that time, depending on accumulated screening history, she may transition to discontinuation discussion.

Worked Example 6: Abnormal Pap Referral to Colposcopy

Beneficiary: 62-year-old woman in Cherokee County, average-risk, every-24-months screening at Piedmont Women's Health.

Most recent Pap test shows HSIL (high-grade squamous intraepithelial lesion). This high-grade abnormality requires immediate colposcopy and biopsy per ASCCP guidelines.

The beneficiary is referred to a gynecologist at Piedmont for colposcopy. Colposcopy with directed biopsy shows CIN 3 (severe dysplasia, pre-cancer). The gynecologist recommends excisional treatment with LEEP.

LEEP is performed at Piedmont as an outpatient procedure. Pathology of the LEEP specimen shows CIN 3 with negative margins.

Billing: Original screening (G0101, Q0091, cytopathology, possibly G0476) under ACA Section 4104 waiver, $0. Colposcopy and biopsy (57452, 57454) subject to standard Part B cost-sharing. LEEP (57461) subject to standard Part B cost-sharing.

The beneficiary enters post-treatment surveillance with annual co-testing for at least 3 years per ASCCP guidelines.

Part 10: Best Practices

Best Practice 1: Document Prior Screening History Carefully

Discontinuation eligibility depends on documented adequate prior negative screening. Carefully documenting prior Pap test, HPV test, and co-test dates and results supports appropriate discontinuation decisions.

Best Practice 2: Discuss Continuation Versus Discontinuation at Age 65

The age 65 transition is a critical decision point. Women with adequate prior negative screening may appropriately discontinue. Women without adequate prior screening or with risk factors should continue. AWV discussions support individualized decisions.

Best Practice 3: Use HPV Co-Testing for Eligible Women

For women age 30 to 65 with average risk, HPV co-testing every 5 years offers improved sensitivity and longer screening intervals compared to cytology alone. Coverage is $0 for eligible co-testing.

Best Practice 4: Document Risk Factors Carefully

High-risk classification (annual rather than every-24-months screening) depends on documented risk factors. Carefully documenting prior cervical cancer, prior CIN 2/3, prior abnormal cytology, DES exposure, HIV, or immunocompromise supports correct risk classification.

Best Practice 5: Coordinate With FQHCs for Underserved Populations

Georgia FQHCs provide cervical cancer screening for medically underserved populations. Medicare beneficiaries in rural counties without local gynecology access may receive screening through FQHCs.

Best Practice 6: Engage African American and Hispanic Women Proactively

Cervical cancer mortality disparities affect African American and Hispanic women. Proactive AWV engagement to address screening adequacy and discontinuation decisions supports informed care for high-disparity populations.

Best Practice 7: Refer Promptly After Abnormal Findings

Abnormal Pap or HPV results require timely follow-up per ASCCP guidelines. Streamlined referral pathways from primary care to gynecology for colposcopy support timely diagnosis and treatment.

Best Practice 8: Coordinate With Gynecologic Oncology for Cervical Cancer

Newly diagnosed cervical cancer requires gynecologic oncology coordination for staging and treatment planning. Major Georgia gynecologic oncology programs include Emory Winship and Augusta University Georgia Cancer Center.

Best Practice 9: Address Post-Hysterectomy Screening Appropriately

Women with prior total hysterectomy (with cervix removal) for benign indications generally do not require continued cervical cancer screening. Documenting hysterectomy status and indication supports appropriate screening decisions.

Best Practice 10: Counsel on Symptoms Despite Discontinuation

Women who appropriately discontinue routine screening should be counseled on symptoms requiring evaluation (postmenopausal bleeding, abnormal discharge, pelvic pain). Symptom-prompted diagnostic evaluation remains available after screening discontinuation.

Best Practice 11: Educate on HPV Natural History

Many beneficiaries do not understand HPV natural history. Educating beneficiaries on HPV transmission, persistence, progression to cervical cancer, and the protective value of vaccination supports informed decisions and reduces stigma.

Best Practice 12: Address Cost-Sharing Distinction at Colposcopy Referral

The cost-sharing distinction between screening ($0) and diagnostic workup (standard Part B cost-sharing) is sometimes a source of beneficiary surprise. Pre-referral counseling addresses expectations.

Best Practice 13: Coordinate With Other Cancer Screening

The AWV is the natural coordinating visit for cervical cancer screening, mammography, and colorectal cancer screening. Aligning these screening discussions supports continuity.

Best Practice 14: Document Shared Decision-Making for Discontinuation

The decision to discontinue routine cervical cancer screening should be documented in the AWV personalized prevention plan with the rationale (adequate prior negative screening, no high-risk factors).

Part 11: Common Issues

Common Issue 1: Inappropriate Continuation of Screening After Age 65

Many women age 65 and older continue routine cervical cancer screening despite adequate prior negative screening that would support discontinuation. AWV-based reassessment supports appropriate discontinuation decisions.

Common Issue 2: Inadequate Documentation of Prior Screening

Discontinuation depends on adequate prior negative screening, but prior screening records are sometimes incomplete or unavailable. Without adequate documentation, continued screening is appropriate.

Common Issue 3: Post-Hysterectomy Screening Confusion

Women with prior hysterectomy may not need continued cervical cancer screening, but the medical record may not always document hysterectomy status clearly. Verifying hysterectomy details supports appropriate decisions.

Common Issue 4: HPV Co-Testing Frequency Misunderstanding

HPV co-testing is covered every 5 years for women age 30 to 65, but some practitioners default to more frequent intervals (yearly or 3-year). Annual HPV co-testing for low-risk women is generally not indicated.

Common Issue 5: High-Risk Misclassification

High-risk classification triggers annual rather than every-24-months screening. Misclassification in either direction produces incorrect screening frequency.

Common Issue 6: Cost-Sharing Surprise on Colposcopy Referral

Beneficiaries who receive callbacks for colposcopy after abnormal screening sometimes do not expect cost-sharing. Pre-referral counseling addresses expectations.

Common Issue 7: Out-of-Network Imaging in Medicare Advantage

Medicare Advantage plans may have gynecology and colposcopy network constraints. Out-of-network use can produce higher cost-sharing.

Common Issue 8: Rural Access Barriers to Colposcopy

Rural beneficiaries needing colposcopy face geographic and transportation barriers. Coordinating travel and follow-up supports timely diagnostic evaluation.

Common Issue 9: Postmenopausal Bleeding Misinterpretation

Postmenopausal bleeding requires diagnostic evaluation regardless of cervical cancer screening status. Sometimes postmenopausal bleeding is attributed to other causes without adequate evaluation for endometrial or cervical malignancy.

Common Issue 10: HPV Vaccination Adult Confusion

Some Medicare-age women ask about HPV vaccination. HPV vaccination is FDA-approved for adults through age 45 (Gardasil 9), but coverage and clinical benefit for older adults is limited. Medicare Part B does not generally cover HPV vaccination as a preventive service.

Common Issue 11: Documentation Gaps After Outside Procedures

When beneficiaries receive colposcopy or LEEP at outside facilities, the procedure and findings may not be communicated back to the primary care record. This produces continuity gaps.

Common Issue 12: Symptomatic Patients Routed to Screening

Women with abnormal bleeding, discharge, or pain require diagnostic evaluation, not screening. Routing symptomatic patients to screening produces incorrect billing and may miss timely diagnosis.

Common Issue 13: ASCCP Guideline Drift

ASCCP cervical cancer management guidelines have evolved (most recently 2019 risk-based management). Practitioners using older guideline frameworks may produce suboptimal management decisions.

Common Issue 14: Cervical Stenosis Sampling Failure

Postmenopausal women may have cervical stenosis preventing adequate Pap sample collection. Documentation of unsatisfactory cytology requires repeat sampling or alternative approaches.

Contacts and Resources

1. Medicare: 1-800-MEDICARE (1-800-633-4227) for general Medicare questions and coverage.
2. Palmetto GBA Medicare Administrative Contractor: 1-866-238-9650 for Medicare claims and coverage in Georgia.
3. Georgia Department of Community Health Member Services: 1-866-211-0950 for Georgia Medicaid coordination.
4. GeorgiaCares SHIP: 1-866-552-4464 for free Medicare counseling.
5. Medicare Rights Center: 1-800-333-4114 for Medicare advocacy and assistance.
6. Atlanta Legal Aid: 404-377-0701 for legal assistance with Medicare issues.
7. Georgia Legal Services Program: 1-800-498-9469 for legal assistance outside metropolitan Atlanta.
8. 211 Georgia: Dial 211 for community resource referrals.
9. Eldercare Locator: 1-800-677-1116 for connection to local aging services.
10. Georgia Department of Public Health: 404-657-2700 for state public health resources including BCCP coordination.
11. American Cancer Society: 1-800-227-2345 for cancer information, support, and resources.
12. National Cervical Cancer Coalition: 1-800-685-5531 for cervical cancer-specific information and patient support.
13. American College of Obstetricians and Gynecologists (ACOG): 202-638-5577 for professional women's health information.
14. American Society for Colposcopy and Cervical Pathology (ASCCP): 301-733-3640 for cervical cancer management guidelines.
15. Emory Gynecology: Academic women's health services in Atlanta.
16. Wellstar Women's Health: Network women's health in north and west Georgia.
17. Piedmont Women's Health: Piedmont Healthcare women's health services across Georgia.
18. Acentra Health QIO: 1-844-455-8708 for Medicare quality of care concerns.

Find personalized help understanding your Medicare cervical cancer screening coverage at brevy.com.